Association between FAS polymorphism and prostate cancer development

• Type: Article in International Scientific Journal
• Date: 2008

Authors

Lima, L (Author) Other; Morais, A (Author) Other; Lobo, F (Author) Other; Calais da Silva, FM (Author) Other; Calais da Silva, FE (Author) Other; Medeiros, R (Author) ICBAS

Journal

Title: Prostate Cancer and Prostatic Diseases

Vol. 11

Pages: 94-98

ISSN: 1365-7852

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 25 Citations

Scopus - 29 Citations

Scientific classification

FOS: Medical and Health sciences > Clinical medicine

Other information

Authenticus ID: P-004-1C4

DOI: 10.1038/sj.pcan.4501002

Abstract (EN): The role of FAS polymorphisms in prostate cancer has not been studied. Using the PCR-based restriction fragment-length polymorphism methodology, we evaluated FAS gene locus -670 genotypes in DNA from 904 men: 657 prostate cancer patients and 247 healthy controls. We found that carriers of AG or GG genotypes have a statistically significant protection ( odds ratio ( OR)=0.30; confidence interval ( CI): 0.20-0.44 and OR 0.22; CI: 0.12-0.74, respectively) for disease with extra-capsular invasion. Taken together, a 72% protection was found for G allele carriers ( OR=0.28; CI: 0.19-0.41). Fas exist as membrane-bound and soluble forms and with opposite roles. They derive from the same gene by alternative splicing. Membrane Fas receptors trigger apoptosis whereas, on the other hand, soluble Fas ( sFas) bind to Fas ligand antagonizing Fas-Fas ligand apoptotic pathway. Our results suggest that G allele may reduce sFas levels preventing the apoptotic inhibition caused by the soluble form.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5